Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Revenue (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Revenue for 14 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue fell 6.51% to $15.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.6 million, a 4.19% decrease, with the full-year FY2025 number at $66.4 million, up 1.84% from a year prior.
  • Revenue was $15.2 million for Q4 2025 at Aytu Biopharma, up from $13.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $30.7 million in Q2 2023 to a low of $13.9 million in Q3 2025.
  • A 5-year average of $20.6 million and a median of $18.7 million in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 61.96% in 2021, then plummeted 52.52% in 2024.
  • Aytu Biopharma's Revenue stood at $23.1 million in 2021, then increased by 13.64% to $26.3 million in 2022, then decreased by 28.66% to $18.7 million in 2023, then fell by 13.48% to $16.2 million in 2024, then fell by 6.51% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Revenue are $15.2 million (Q4 2025), $13.9 million (Q3 2025), and $15.1 million (Q2 2025).